[A16-75] Elbasvir/grazoprevir (chronic hepatitis C) - Benefit assessment according to §35a Social Code Book V
Last updated 15.06.2017
Project no.:
A16-75
Commission:
Commission awarded on 14.12.2016 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-143 | Elbasvir/grazoprevir (chronic hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2017-06-15 A G-BA decision was published.